CEPI establishes Representative Office in Shanghai, China

CEPI_Shanghai Regional Office

CEPI, the Coalition for Epidemic Preparedness Innovations, has officially announced the legal establishment of a Representative Office in Shanghai, China. Through its Shanghai Representative Office, CEPI will seek cooperation with China in the prevention and control of pandemic diseases, including funding of public health research projects, research and development of vaccines, and international scientific, technology and development cooperation and exchanges.

CEPI is a global organisation, working on global solutions to global issues. We already have offices in Oslo, London and Washington D.C., and I am pleased that we can now add the CEPI Shanghai Representative Office to that list. The CEPI Shanghai Representative Office will facilitate our collaboration with China, and we look forward to working closely with Chinese partners in the fight against COVID-19

Dr. Richard HatchettChief Executive Officer, CEPI

We welcome the establishment of the Representative Office of CEPI in Shanghai, which is of great significance to the promotion of international scientific and technological cooperation and exchanges between Shanghai and the world in the field of epidemic prevention and innovation. We will actively promote practical and efficient cooperation between CEPI and relevant research institutions to make contributions to the fight against COVID-19

Mr. Quan ZhangChairman of STCSM


Click here for Chinese version of this announcement

About CEPI

CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at the World Economic Forum at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. To date, CEPI has initiated 8 partnerships to develop vaccines against the novel coronavirus. The programmes will leverage rapid response platforms already supported by CEPI as well as new partnerships. The aim is to advance COVID-19 vaccine candidates into clinical testing as quickly as possible.

Before the emergence of COVID-19, CEPI's priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).

Follow our news page for the latest updates.